Category Archives: USTR 301 report

MSF: U.S. Special 301 report undermines efforts to lower medicine prices globally

Source: MSF India 30th April, 2019   On the eve of World Intellectual Property Day, the United States Trade Representative released its annual “Special 301 Report.” Developing countries like India and Malaysia once again face unfair pressure from the US government over … Continue reading

Posted in USTR, USTR 301 report | Leave a comment

US “Special 301″ Report undermines efforts to lower medicine prices globally: Leena Menghaney

Source: Pharma Express 30th April, 2019   Leena Menghaney, Head-South Asia, Médecins Sans Frontières (MSF), discusses the release of United States Trade Representative (USTR)’s 2019 “Special 301″ Report and its effect on pharma industries in developing nations The United States … Continue reading

Posted in USTR 301 report | Leave a comment

‘Big Pharma’ backs Trump’s Asia trade squeeze

Source: ASIA TIMES | May 03, 2018 US President Donald Trump’s administration stands accused of deploying bullying tactics to promote greater market access for American pharmaceutical companies by stifling the production and distribution of more affordable, and usually totally legal, … Continue reading

Posted in Special 301 report, US Pressure, USTR 301 report | Leave a comment

LIES, DISTORTIONS, AND FALSE PROMISE: THE U.S. POSITION ON COMPULSORY LICENSES IN THE 2018 SPECIAL 301 REPORT

Source: infojustice.org | May 1, 2018 Every year since the late 1980s, the U.S. has published a Special 301 Watchlist targeting countries that U.S. intellectual property-based industries, like Big Pharma, complain about. Once again the U.S. is unbelievably duplicitous in its 2018 … Continue reading

Posted in Special 301 report, USTR, USTR 301 report | Leave a comment

USTR Priority Watch List calls out countries for protecting public health

Source: MSF Access | April 27, 2018 NEW YORK, APRIL 27, 2018-The Office of the United States Trade Representative (USTR) released its annual “Special 301 Report” today, which reviews countries based on their intellectual property (IP) rights protection and enforcement. … Continue reading

Posted in Special 301 report, USTR, USTR 301 report | Leave a comment

30+ Civil Society Orgs to USTR: Stop Threatening to Block Colombia’s OECD Accession over Pharma/Biotech Lobby Interests

Source: Knowledge Ecology International | March 20, 2018 A broad international coalition of over 30 human rights organizations, including some across the United States and Latin America, have come together to ensure that providing access to health care doesn’t come at … Continue reading

Posted in Uncategorized, USTR, USTR 301 report | Leave a comment

New Government Report Affirms India’s Patient-First Commitment on Pharma Patents

A government review says it is well within its rights to put Indian patients and the Indian generic pharmaceuticals industry first. As various countries await the US’s ‘Special 301 report’, where the US government discusses intellectual property negotiations with other … Continue reading

Posted in Indian Patent Law, Patent, Uncategorized, USTR, USTR 301 report | Leave a comment